πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

229 results for β€œOvid” Clear

  1. Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28

    Jiangsu Province Centers for Disease Control and Prevention

    COVID-19

    phase 1 mab completed

    1 trial

  2. Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 Β΅g

    Hospital Authority, Hong Kong

    COVID-19 Pandemic

    phase 1 mab active

    1 trial

  3. randomized, double-blinded, placebo-controlled

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prevention of COVID-19 Caused by SARS-CoV-2

    phase 1 mab active

    1 trial

  4. AZD1222

    AstraZeneca

    COVID-19, SARS-CoV-2

    approved mab terminated

    1 trial

  5. Adult group in immunogenicity and safety study of combined immunization

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial

  6. Aerosolized 13 cis retinoic acid plus Vitamin D

    The First People's Hospital of Lianyungang

    Post COVID-19 Anosmia (Loss of Smell)

    approved small molecule active

    1 trial

  7. Azvudine

    The First People's Hospital of Lianyungang

    COVID-19

    approved small molecule active

    1 trial

  8. BIMERVAX LP.8.1 emulsion for injection COVID-19 Vaccine (recombinant, adjuvanted)

    Hipra Human Health S.L.

    COVID-19

    approved small molecule active

    1 trial

  9. BIMERVAX LP.8.1 emulsion for injection COVID-19 Vaccine (recombinant, adjuvanted), Spikevax bivalent Original/Omicron BA.1 25 micrograms/25 micrograms dispersion for injection COVID 19 mRNA Vaccine, Comirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, Spikevax 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine, Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine, Nuvaxovid dispersion for injection COVI

    The George Institute

    COVID-19 infection

    approved small molecule active

    1 trial

  10. COVAX

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    approved mab active

    1 trial

  11. COVID-19 Vaccine (Vero cell), Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial

  12. Comirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, Spikevax 0.2 mg/mL dispersion for injection COVID-19 mRNA Vaccine, EVUSHELD 150 mg + 150 mg solution for injection, Xevudy 500 mg concentrate for solution for infusion, Nuvaxovid dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)

    The George Institute

    Covid-19 infection

    approved small molecule active

    1 trial

  13. Covid-19 vaccine (0-1-4 schedule)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    approved mab active

    2 trials

  14. ESTRIOL , ESTRADIOL HEMIHYDRATE, PROMESTRIENE, PROGESTERONE, ESTRADIOL VALERATE

    The George Institute

    Cervical cancer

    approved small molecule active

    1 trial

  15. Experimental Group

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    4 trials

  16. Experimental vaccine 1

    Sinovac Research and Development Co.,

    COVID-19

    approved mab on hold

    1 trial

  17. High-dosage SARS-CoV-2 vaccine

    Sinovac Research and Development Co.,

    COVID-19

    approved mab active

    1 trial

  18. High-dosage of COVID-19 vaccine (Vero cell), Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial

  19. Inactivated COVID-19 vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    approved mab active

    1 trial

  20. Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2

    Sinovac Research and Development Co.,

    COVID-19

    approved mab active

    1 trial

  21. Inactivated SARS-CoV-2 Vaccine (Vero cellοΌ‰

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial

  22. Pfizer-BioNTech mRNA COVID-19 vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    COVID -19

    approved small molecule active

    1 trial

  23. SARS-CoV-2 Inactivated Vaccine

    Sinovac Research and Development Co.,

    COVID-19

    approved mab active

    2 trials

  24. Sertraline Hydrochloride

    The First People's Hospital of Lianyungang

    COVID-19 Vaccine Adverse Reaction

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources